Free Trial
NASDAQ:LMAT

LeMaitre Vascular Q2 2025 Earnings Report

LeMaitre Vascular logo
$83.68 -2.07 (-2.41%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$83.66 -0.02 (-0.02%)
As of 07/11/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LeMaitre Vascular EPS Results

Actual EPS
N/A
Consensus EPS
$0.57
Beat/Miss
N/A
One Year Ago EPS
N/A

LeMaitre Vascular Revenue Results

Actual Revenue
N/A
Expected Revenue
$62.48 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

LeMaitre Vascular Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

LeMaitre Vascular Earnings Headlines

LeMaitre Vascular, Inc. (LMAT) Balance Sheet - Yahoo Finance
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
LMAT LeMaitre Vascular, Inc. - Seeking Alpha
See More LeMaitre Vascular Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LeMaitre Vascular? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LeMaitre Vascular and other key companies, straight to your email.

About LeMaitre Vascular

LeMaitre Vascular (NASDAQ:LMAT) (NASDAQ: LMAT) is a Massachusetts‐based medical device company specializing in the development, manufacturing and marketing of specialty vascular surgical devices. Since its founding in 1981 by vascular surgeon Dr. George D. LeMaitre, the company has focused on addressing unmet clinical needs in the treatment of peripheral artery and venous diseases. Headquartered in Burlington, Massachusetts, LeMaitre Vascular has maintained its public listing since 2004 and continues to operate with a commitment to quality, innovation and physician collaboration.

The company’s product portfolio spans a broad range of vascular interventions, including valvulotomes for in situ vein bypass procedures, occlusion balloons for temporary arterial blockages, endoscopic vessel harvesting systems and plasma‐derived patch materials for blood vessel repair. LeMaitre Vascular also offers a suite of atherectomy devices, angioplasty balloons, specialty catheters and hemostatic agents designed to streamline surgical workflows and improve patient outcomes. Ongoing investments in research and development have expanded its offerings to include advanced sealing and anastomotic devices that meet evolving clinical requirements.

LeMaitre Vascular serves physicians and healthcare institutions in over 80 countries across North America, Europe, Latin America and the Asia-Pacific region. The company employs a hybrid commercial model with direct sales operations in key markets and established distribution partnerships in regions with emerging demand. Its global footprint enables close collaboration with vascular and cardiovascular surgeons, interventional radiologists and treatment centers that manage chronic peripheral artery disease and venous insufficiency.

Leadership remains rooted in the company’s founder‐driven ethos, with a management team committed to advancing minimally invasive vascular solutions. Under the guidance of President and Chief Executive Officer Mark Dunn and supported by a seasoned board of directors, LeMaitre Vascular emphasizes customer support, regulatory compliance and strategic acquisitions to drive sustainable growth. With more than four decades of industry experience, the company continues to leverage physician feedback and clinical evidence to refine its products and expand into new markets.

View LeMaitre Vascular Profile

More Earnings Resources from MarketBeat